BioCryst Pharmaceuticals Inc. undefined shares rallied in the extended session Thursday after the drug maker said it was starting a clinical trial to test...
BioCryst Pharmaceuticals Inc.
shares rallied in the extended session Thursday after the drug maker said it was starting a clinical trial to test its COVID-19 treatment. BioCryst shares surged 35% after hours, following a 3.5% rise to close the regular session at $2.07. The company said it opened a randomized, double-blind, placebo-controlled clinical trial to test the drug galidesivir in treating patients with COVID-19. The study, which is being funded by the U.S.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Here's what happened to the stock market on ThursdayStocks rallied to end a historic week after the Fed unveiled even more measures to help the economy during the coronavirus outbreak.
Lire la suite »
Sen. Kelly Loeffler will liquidate individual stock shares after coronavirus trade furorSen. Kelly Loeffler and her husband Jeff Sprecher, CEO of the owner of the New York Stock Exchange, were criticized for selling millions of dollars in stock amid the coronavirus pandemic.
Lire la suite »
Invoking medieval invaders, Putin rallies Russians against coronavirusPresident Vladimir Putin on Wednesday likened Russia's fight against the novel coronavirus to its battles against medieval invaders and said the next few weeks would be decisive.
Lire la suite »